{
    "clinical_study": {
        "@rank": "43723", 
        "arm_group": [
            {
                "arm_group_label": "ASP2408 low dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP2408 middle dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP2408 high dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of\n      single subcutaneous dose of ASP2408 in non-elderly healthy adult male subjects. The\n      pharmacodynamics of  ASP2408 is also being evaluated."
        }, 
        "brief_title": "A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy", 
            "Pharmacokinetics of ASP2408"
        ], 
        "detailed_description": {
            "textblock": "This clinical study will be conducted as a double-blind, placebo-controlled, single\n      ascending subcutaneous dose study. As shown in the table below, the study will be conducted\n      using 3 cohorts, to which a total of 24 subjects will be randomly assigned (18 subjects\n      receiving ASP2408 and 6 subjects receiving placebo). Each cohort will consist of 8 subjects,\n      who will be randomly assigned to either the ASP2408 group or the placebo group at the ratio\n      of 3 to 1.\n\n      Each subject will need to be hospitalized until Day 8 (start date of study drug\n      administration will be regarded as Day 1) and will be observed until Day 90. The\n      investigator or subinvestigator will carefully observe each subject for any sign or symptom\n      of adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI (at screening): \u2265 17.6 kg/m2, < 26.4 kg/m2\n\n          -  Healthy, as judged by the investigator or subinvestigator based on the results of\n             medical examination (subjective symptoms and objective findings) and all tests\n             obtained at screening and during the period from hospitalization (Day \u22122) to\n             immediately before study drug administration\n\n          -  Subjects who agree to use effective contraception until 90 days after study drug\n             administration\n\n        Exclusion Criteria:\n\n          -  Received any investigational drugs in other clinical or post-marketing studies within\n             120 days before the study or is scheduled to receive any investigational drugs\n\n          -  Donated 400 mL of whole blood within 90 days before the study or during the period\n             from the screening, 200 mL of whole blood within 30 days, or blood components within\n             14 days before the study, or is scheduled to donate 400 mL of whole blood or blood\n             components\n\n          -  Received medication within 7 days before hospitalization (Day \u22122) or is scheduled to\n             receive medication\n\n          -  Received systemic medications influencing immune functions (e.g., steroids,\n             tacrolimus hydrate, anticancer drugs, and biological products) within 365 days before\n             study drug administration\n\n          -  Received a live virus vaccine (e.g., BCG, polio, measles, and rubella) within 180\n             days before study drug administration, or cannot agree not to receive these vaccines\n             for 180 days after study drug administration\n\n          -  Received a live virus vaccine (e.g., BCG, polio, measles, and rubella) within 180\n             days before study drug administration, or cannot agree not to receive these vaccines\n             for 180 days after study drug administration\n\n          -  A deviation from the normal range of blood pressure, pulse rate, body temperature, or\n             standard 12-lead ECG (see Table 3.3-1) at screening or the day before study drug\n             administration (Day \u22121)\n\n          -  Any deviation of the normal ranges in laboratory tests before study drug\n             administration\n\n          -  Failure to meet any criteria for standard 12-lead ECG for QT assessment at screening\n\n          -  A positive result for tuberculosis test\n\n          -  Concurrent or history of drug allergies, anaphylaxis, or severe allergic reaction\n\n          -  Upper GI disease\n\n          -  Concurrent or previous hepatic disease (e.g., viral hepatitis and drug-induced liver\n             injury)\n\n          -  Concurrent or previous heart disease (e.g., congestive heart failure, angina\n             pectoris, and arrhythmia requiring treatment)\n\n          -  Concurrent or previous respiratory disease (e.g., bronchial asthma and chronic\n             bronchitis; except for a history of childhood asthma)\n\n          -  Previous operation of gut excision\n\n          -  Concurrent or previous renal disease (e.g., acute renal failure, glomerulonephritis,\n             and interstitial nephritis; except for a history of calculus)\n\n          -  Concurrent or previous endocrine disease (e.g., hyperthyroid, abnormality of growth\n             hormone)\n\n          -  Concurrent or previous cerebrovascular disorder (e.g., cerebral infarction)\n\n          -  Concurrent or previous malignant tumor\n\n          -  Concurrent or previous serious infection (e.g., sepsis, pneumonia requiring\n             hospitalization, and pyelonephritis)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "44 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140125", 
            "org_study_id": "2408-CL-9101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ASP2408 low dose group", 
                    "ASP2408 middle dose group", 
                    "ASP2408 high dose group"
                ], 
                "description": "subcutaneous administration", 
                "intervention_name": "ASP2408", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "description": "subcutaneous administration", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "ASP2408", 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kyushu", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase I Study of ASP2408 -Subcutaneous Single-dose, Placebo-controlled Study in Non-elderly Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety assessed by the incidence of adverse events, vital signs, lab tests, and 12-lead ECG", 
            "safety_issue": "No", 
            "time_frame": "Up to 90 days after administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140125"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The pharmacokinetic analysis employed non-compartmental methods using serum concentrations of ASP2408. The following pharmacokinetic parameters were estimated: AUCinf, AUClast, Cmax, CL/F, tmax, t1/2, and Vz/F.", 
                "measure": "Pharmacokinetics of serum ASP2408", 
                "safety_issue": "No", 
                "time_frame": "On day-1, day-2, day-3, day-4, day-5, day-6, day-7, day-8, day-9, day-11, day-13, day-15, day-22, day-29 day-43, day-60 and day-90"
            }, 
            {
                "measure": "CD80/CD86 receptor occupancy", 
                "safety_issue": "No", 
                "time_frame": "On day-1, day-2, day-3, day-5, day-8, day 15, day-22, day-29 and day-90"
            }, 
            {
                "measure": "Total lymphocyte count", 
                "safety_issue": "No", 
                "time_frame": "On day-1, day-2, day-3, day-5, day-8, day 15, day-22, day-29 and day-90"
            }, 
            {
                "measure": "Peripheral blood lymphocyte subset", 
                "safety_issue": "No", 
                "time_frame": "On day-1, day-2, day-3, day-5, day-8, day 15, day-22, day-29 and day-90"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}